OncoMatch/Clinical Trials/NCT03351348
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
Is NCT03351348 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Bupivacaine for breast cancer.
Treatment: Bupivacaine — The purpose of this study is to compare using FDA-approved bupivacaine (a numbing medicine), along with the usual medications for post-operative pain control to using the usual medications for postoperative pain control alone. The addition of bupivacaine to the surgical wound site with the usual pain medications could better manage your pain immediately after surgery and reduce the amount of opioid medications taken after surgery. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (Consent and follow-up only) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Consent and follow-up only) · Montvale, New Jersey
- Memorial Sloan Kettering Commack (Consent and follow-up only) · Commack, New York
- Memorial Sloan Kettering Westchester (Consent and follow-up only) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify